Epirus Biopharmaceuticals (Switzerland) GmbH
Quick facts
Phase 3 pipeline
- BOW015
BOW015 is a biosimilar of a biologic therapeutic targeting a specific disease pathway, designed to provide equivalent efficacy and safety to its reference product.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Epirus Biopharmaceuticals (Switzerland) GmbH portfolio CI brief
- Epirus Biopharmaceuticals (Switzerland) GmbH pipeline updates RSS
Frequently asked questions about Epirus Biopharmaceuticals (Switzerland) GmbH
What is Epirus Biopharmaceuticals (Switzerland) GmbH's pipeline?
Epirus Biopharmaceuticals (Switzerland) GmbH has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include BOW015.
Related
- Sector hub: All tracked pharma companies